Update: Portfolio expansion
Abzena has announced that two partners have started clinical studies with antibody candidates developed using Abzena’s humanising technology. An undisclosed US major pharma company has initiated a Phase I trial in neurodegenerative conditions and Therapure Innovations has commenced a Phase I study for TBI 304H in chemotherapy-induced anaemia. The disclosed clinical stage portfolio now stands at eight candidates, on which Abzena could receive small royalty revenues, which in aggregate may be substantial and highlights the longer-term investment case.Abzena is providing a range of complementary services and technologies for the selection, development and manufacture of biopharmaceuticals.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.